uploads/2018/03/Cardiovascular.png

How Merck’s Cardiovascular Segment Performed in 4Q17 and 2017

By

Updated

Zetia’s revenue trends

In 4Q17, Merck’s (MRK) Zetia reported revenues of $323 million, which was ~44% lower on a YoY (year-over-year) basis and a 1% rise on a QoQ (quarter-over-quarter) basis.

In 4Q17, in the US and international markets, Zetia generated revenues of $54 million and $269 million, respectively, which reflected a ~84% decline and a 12% rise YoY, respectively.

In fiscal 2017, Zetia reported revenues of $1.34 billion, compared with $2.56 billion in 2016, which reflected a ~48% YoY decline. In 2017, in the US and international markets, Zetia reported revenues of $352 million and $992 million, respectively, compared with $1.6 billion and $972 million in 2016, which was ~78% lower and 2% higher YoY, respectively.

Zetia is witnessing stiff competition in the marketplace primarily due to increased competition from the generic versions of Zetia. Teva Pharmaceuticals (TEVA) has started commercializing the generic versions of Zetia in the US since June 2017.

Article continues below advertisement

Vytorin revenue trends

In 4Q17, Merck’s Vytorin generated revenues of $186 million, which reflected a ~38% decline YoY and a 31% rise QoQ. In 4Q17, in the US and in international markets, Vytorin generated revenues of $11 million and $11 million and $176 million, respectively, which reflected a ~92% rise and 5% growth YoY.

In fiscal 2017, Vytorin generated revenues of $751 million, compared with $1.14 billion in 2016, which reflected a ~34% YoY decline. In 2017, in the US and in international markets, Vytorin reported revenues of $124 million and $627 million, respectively, compared with $473 million and $668 million in 2016, which reflected ~74% and ~6% declines on a YoY basis.

Merck’s Vytorin also faces stiff competition due to the availability of generic versions of the drug in the US. In the US, Teva Pharmaceuticals and Impax Laboratories (IPXL) commercializes the generic version of Vytorin.

Atozet revenue trends

In 4Q17, Atozet generated revenues of $54 million, which with ~8% higher on a YoY basis and a ~8% fall QoQ. For 2017, Atozet reported revenues of $225 million, which reflected a ~54% YoY rise.

Adempas revenue trends

In 4Q17, Adempas reported revenues of $79 million, which was 61% higher on a YoY basis and 13% higher QoQ. In 2017, Merck’s Adempas generated revenues of $300 million, compared with $169 million in 2016, which reflected a ~78% rise YoY.

Bayer (BAYZF) commercializes Adempas in the US, while Merck commercializes the drug in the rest of the world.

Advertisement

More From Market Realist